Hirulog(TM) is a thrombin catalytic site inhibitor which exhibits spec
ificity for the anionic binding exosite of alpha thrombin. Here, we ha
ve evaluated the effect of Hirulog(TM) (1, 5 and 10 mg/kg, 30 min pret
reatment) in a rat model of endotoxemia. Intravenous injection of lipo
polysaccharide from E. coli (25 mg/kg; serotype 0127:B8) caused decrea
ses in blood pressure which were significantly reduced (about 60%) in
animals pretreated with Hirulog(TM). Rat survival to endotoxin was sig
nificantly increased in Hirulog(TM) pretreated group (5 and 10 mg/kg)
up to 24 hours. Hirulog(TM) at the dose of 10 mg/kg inhibited both end
otoxin-induced leukopenia at 30 and 60 minute points and thrombocytope
nia at 30 minute point but not at 90 and 120 minute points. Fibrinogen
levels were significantly reduced after 2 hours following endotoxin a
dministration. Pretreatment with Hirulog(TM) (5-10 mg/kg i.v.) 30 min
prior to administration of endotoxin prevented changes in fibrinogen p
lasma levels. These results demonstrate that Hirulog (TM)-induced inhi
bition of thrombin is effective in reducing toxic and lethal effects o
f endotoxin.